 |
 |
7:30 AM-9:00 AM
Oral Session, 288-290: Clinical Care - Transplantation Regimen Toxicities and Engraftment: Ways to Improve Outcome of alloSCT for Malignant and Genetic Diseases
865 Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment. Rachel B. Salit, et al.
867 Delayed Platelet Recovery After Allogeneic Peripheral Blood, Marrow and Umbilical Cord Stem Cell Transplantation: Risk Factors and Clinical Outcomes. Pablo A Ramirez, et al.
Oral Session, 291-292: Clinical Results - Alternative Donor Transplantation III
871 Impact of Donor-Recipient Ethnicity On Risk of Acute Graft-Versus-Host Disease, Leukemia Relapse and Survival in Hematopoietic Stem Cell Transplantation From HLA-Compatible Unrelated Donors. A Report From the International Histocompatibility Workshop Group. Yasuo Morishima, et al.
872 Comparison of Outcomes for Non-Myeloablative (NMA) and Myeloablative (MA) Conditioning for Adults with Acute Lymphoblastic Leukaemia (ALL) in First and Second Complete Remission (CR): a Center for International Blood and Marrow Transplant Research (CIBMTR) Analyisis. David I. Marks, et al.
12:00 PM - 1:30 PM
Poster Session: Vascular Biology
3042 Augmented Revascularization and Recovery From Acute Limb Ischemia After Transplantation of Human Umbilical Cord Blood Progenitor Cells with High Aldehyde Dehydrogenase Activity. David M Putman, et al.